Recent News

• 02.10.2026 - FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
• 02.05.2026 - FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
• 01.20.2026 - FibroBiologics to Present at the DealFlow Discovery Conference
• 01.07.2026 - FibroBiologics CEO Issues Letter to Shareholders
• 01.06.2026 - FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
• 01.05.2026 - FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
• 12.31.2025 - FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
• 12.16.2025 - FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 12.15.2025 - FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Recent Filings

• 02.06.2026 - 8-K Current report
• 01.02.2026 - 8-K Current report
• 12.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.30.2025 - EFFECT Notice of Effectiveness
• 12.29.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 12.29.2025 - DEF 14A Other definitive proxy statements
• 12.23.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 12.18.2025 - PRE 14A Other preliminary proxy statements
• 12.18.2025 - DEF 14A Other definitive proxy statements
• 12.16.2025 - D Notice of Exempt Offering of Securities